|
Market Cap (4-Jun) $113,166,768 (1,377th) |
Close (30-Jun) $0.028 |
Volume (30-Jun) 622,600 |
Shortsold (30-Dec) 421 (0.00%) (625th) |
|
52w High $1.44 |
52w Low $0.175 |
P/E - |
EPS -0.02 |
NYR released this announcement to the ASX on 30 August 2021, 16:44. The announcement is marked as price sensitive, and is 2 page(s) in length and 226.37kb in size.
You can view all announcements from NYR and see how they appear on a price chart on the announcements page.
At the date of this announcement, NYR was 0.001% short sold according to ASIC data. It was ranked the 633rd most shorted stock on the ASX. It is now ranked as the 625th most shorted stock on the ASX with 0.000% of total shares short sold as of the latest reported data (30 December 2025).
| Other Recent Announcements from NYR | |
|---|---|
| Cholesterol-Lowering Program Update | 26 June 2023, 9:55 |
| Brain Injury Program Preclinical Development Update | 9 June 2023, 8:18 |
| Cholesterol-Lowering Program Preclinical Studies Completed | 26 May 2023, 8:44 |
| Preliminary Final Report | 30 August 2021, 16:44 |
| Appendix 4G and Corporate Governance Statement | 30 August 2021, 16:40 |
| NYX-PCSK9i In Vivo Study Exploratory Analysis Results | 13 August 2021, 9:00 |
| Nyrada Announces US Patent Grant for PCSK9 Inhibitor | 30 July 2021, 8:17 |
You must be logged in to post a reply.
Nyrada Inc 